Company

Noile-Immune Biotech

ノイルイミューン・バイオテック

4893 · TSE · Pharmaceutical

Financials Company only

Revenue¥5.00m−34.1% year on yearCompany only · FY12/25

Ordinary profit−¥791mCompany only · FY12/25

Revenue

¥101mFY12/21

¥626mFY12/22

¥317mFY12/23

¥7.59mFY12/24

¥5.00mFY12/25

Ordinary profit

−¥793mFY12/21

−¥384mFY12/22

−¥1.13bnFY12/23

−¥962mFY12/24

−¥791mFY12/25

Op. cash flow

−¥777mFY12/21

−¥107mFY12/22

−¥873mFY12/23

−¥888mFY12/24

−¥752mFY12/25

Employees23 peopleFY12/25

Average salary¥7.08mFY12/25

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history

Five-year history
Fiscal year	Revenue	Ordinary profit	EPS	Total assets	Net assets	Op. cash flow
FY12/25	¥5.00m−34.1% year on year	−¥791m	−¥18.33	¥4.01bn	¥3.93bn	−¥752m
FY12/24	¥7.59m−97.6% year on year	−¥962m	−¥22.28	¥4.80bn	¥4.73bn	−¥888m
FY12/23	¥316.82m−49.4% year on year	−¥1,128m	−¥27.25	¥5.78bn	¥5.69bn	−¥873m
FY12/22	¥625.78m+521.2% year on year	−¥384m	−¥9.87	¥4.64bn	¥4.30bn	−¥107m
FY12/21	¥100.73m	−¥793m	−¥20.75	¥4.27bn	¥4.19bn	−¥777m

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100XSP4 · Japan GAAP. Each figure's years come from one report's five-year summary.